EAGAN, Minn.--(BUSINESS WIRE)--Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company’s immunotherapy in Phase 3 drug development for colorectal cancer. The new findings will be presented today at the VIC Congress - Vaccines, Immunotherapies and Cell Therapies, in Brussels.
Help employers find you! Check out all the jobs and post your resume.
